Our Take
Lilly executed a compliance ultimatum that hospitals say was unreasonable, but the real issue is whether HRSA will enforce the 340B program's terms or side with providers.
Why it matters
The 340B program is how safety-net hospitals and clinics buy drugs at steep discounts to stretch thin budgets. When manufacturers weaponize paperwork compliance, access costs rise fastest for the patients who can least afford it.
Do this week
Hospital compliance officers: audit your 340B documentation against Lilly's stated requirements before month-end so you can remediate gaps before other manufacturers follow.
Lilly enforced new 340B documentation rules unilaterally
Eli Lilly halted 340B program discounts to hospitals that did not meet new paperwork and verification requirements the company imposed unilaterally. The move came late last week, after Lilly had set a compliance deadline that hospitals say was unreasonable given the scope of the new rules.
The 340B program is a federal mandate that requires drug manufacturers to offer steep discounts to eligible healthcare providers, including safety-net hospitals, disproportionate-share hospitals (DSH), and some clinics. Lilly's decision to withhold discounts for non-compliance is a departure from industry practice and has triggered urgent calls from hospital groups asking the Department of Health and Human Services' Health Resources and Services Administration (HRSA) to step in.
The company has not publicly detailed the specific requirements. Hospital administrators have characterized the new rules as opaque and the timeline as punitive. HRSA oversees the 340B program but does not pre-approve manufacturer compliance rules; that enforcement gap is now in focus.
The 340B program funds the margins that keep safety-net hospitals open
The 340B discount is not a negotiated price; it is a statutory obligation. Manufacturers must offer covered entities a maximum price tied to their lowest-price sales to wholesalers. For hospitals that serve uninsured and Medicaid populations, the 340B discount often funds clinic operations, emergency departments, and outpatient care that would otherwise run at a loss.
When a manufacturer conditions discounts on paperwork standards not mandated by statute, it shifts compliance risk and cost onto the provider side. Lilly's move creates a template for other manufacturers to follow. If the practice spreads without HRSA oversight, the cumulative effect could squeeze the operating margins that safety-net hospitals depend on.
The political exposure is also real. HRSA answers to the Department of Health and Human Services, which has made safety-net hospital funding a priority. A visible manufacturer enforcement action will likely draw congressional and agency scrutiny.
Hospitals should document 340B compliance immediately
Hospital procurement and compliance teams need to audit their 340B documentation against Lilly's stated requirements without delay. Request the full text of any new rules directly from your Lilly representative and create a remediation timeline. Do not assume the company will extend the deadline again or that other manufacturers will not follow suit.
In parallel, have your hospital's government affairs or legal team file a comment or complaint with HRSA requesting clarity on whether manufacturers can unilaterally impose verification rules outside the statutory program terms. The agency's response will determine whether this becomes an industry standard or a one-time escalation.